Soleno Therapeutics Inc (SLNO): Debt to Book Capitalization Ratio

Corporate company logo of Soleno Therapeutics Inc (SLNO)

The development of Soleno Therapeutics (SLNO) is constrained by global patent disputes and risks of raw material supply chain disruptions. However, the success of clinical trials has sparked euphoria among physicians and investors, driving brand confidence to a maximum. This price chart, where the indicator stands at 0.12, complements data regarding strict adherence to temperature controls during drug transportation. Soleno Therapeutics (SLNO) specializes in the therapy of metabolic disorders.

SLNO Soleno Therapeutics Corp: Debt to Book Value in the range 07/04/2022 - 05/30/2026

Comprehensive metric breakdowns and analytics for Soleno Therapeutics Inc (SLNO)

- current price and projected stock value:
Stock Price Soleno Therapeutics|SLNO - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Soleno Therapeutics Corp|SLNO - Value Adjusted for Debt and Cash
- book value of equity indicators:
Net Assets per Single Share Soleno Therapeutics|SLNO - Company Net Assets|Market Capitalization to Book Value Ratio soleno.life|SLNO - Company Total Assets
- debt and solvency information:
Total Debt to Equity Ratio Soleno Therapeutics|SLNO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Soleno|SLNO - Company Total Debt|Debts to Book Capitalization Soleno Therapeutics Corp|SLNO - Long-Term Debt|Company Current Liabilities Soleno Therapeutics|Quick Ratio soleno.life
- business earnings and investment ratios data:
SLNO - Net Profit
Analysis of all company metrics:Soleno Therapeutics SLNO
Manufactured products of Soleno

The financial stability of Soleno Therapeutics (SLNO) depends on its ability to fund the market launch of DCCR without incurring a critical debt load. By analyzing the current debt level relative to balance sheet capital, an investor assesses the debt-to-equity ratio, which helps identify the risk of overheating or the underutilization of leverage to accelerate the growth of business value.

Competitor analysis

Debts to Book Capitalization ASND (Ascendis Pharma A/S)|Debts to Book Capitalization madrigalpharma.com MDGL|CORT - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio RYTM (Rhythm Pharma)|Akero Therapeutics Inc (AKRO) - Debt to Book Capitalization Ratio|Debt to Book Value Metsera Therapeutics|MLTX (MoonLake Immunotherapeutics) - Debts to Book Capitalization|Debts to Book Capitalization crinetics.com|Debt to Book Value NAMS (NewAmsterdam Pharma Company N.V.)|FOLD (Amicus Therapeutics Inc) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio 89bio Corp ETNB|AGIO - Debt to Book Value|Structure Therapeutics - Debts to Book Capitalization|Debts to Book Value mimedx.com|RZLT (Rezolute) - Debt to Book Value|LXRX: Debt to Book Capital|MBX (MBX Bio) - Debts to Book Capitalization|Debts to Book Capitalization Altimmune Pharma|Debts to Book Capitalization AARD|Debt to Book Capitalization Ratio SGMT (sagimet.com)|Debt to Book Capitalization Ratio BioAge BIOA|Biomea Fusion Inc (BMEA) - Debts to Book Value|QNCX - Debt to Book Capitalization Ratio|GUTS: Debt to Book Capitalization Ratio|VTVT: Debts to Book Capitalization|ATPC - Debts to Net Assets|Debt to Book Capitalization Ratio Pluristem Therapeutics|Synlogic Corp (SYBX) - Debts to Net Assets|Debt to Book Capitalization Ratio Lipocine Corp (LPCN)|Debt to Book Value matinasbiopharma.com MTNB|Debt to Book Capitalization Ratio Spruce Biosciences, Inc. SPRB|Debts to Net Assets galecto.com (GLTO)|CTCX - Debt to Book Capitalization Ratio|Debts to Book Value Lumos Pharma Inc|Organovo Holdings Inc (ONVO) - Debt to Book Capitalization Ratio|RDUS (Radius Pharmaceuticals) - Debt to Book Capitalization Ratio